Because a pharmacopoeial monograph for 4-butylresorcinol as an oral or injectable API is not established in USP–NF or Ph. Eur. at the time of writing, all dosage-form limits and processing windows are development-stage and must be justified under ICH Q3A, Q3C, Q3D, and ICH Q8. During direct-compression development of low-dose 4-butylresorcinol tablets, the crystalline API’s low melting point—reported in the range of 50–53 °C—creates a narrow thermal processing window. On rotary tablet presses without cooled tooling, punch-face temperatures can rise above 35 °C during extended campaigns, leading to localized softening, picking, and film formation on the tablet surface. A spiral jet mill with chilled nitrogen is therefore used to reduce the API to a target particle-size distribution of d90 15–25 µm; published data for the optimum particle size for this specific compound in direct-compression blends is limited, and the target is confirmed by dissolution performance rather than assumed. The milled API is blended with microcrystalline cellulose, lactose monohydrate, and crospovidone in a low-shear tumble blender; magnesium stearate is then introduced at 0.5 % w/w of the final blend to minimize hydrophobic coating of the API surface. Tablet breaking force is evaluated according to USP <1217>, and a development-stage target of 60–100 N for an 8 mm round biconvex core is used only after compressibility profiling under USP <1062>. Content uniformity is assessed by USP <905> with an acceptance value of AV ≤15.0 for low-dose products. The primary batch-scale failure mode observed in compression of this low-melting phenol is adhesion to punch faces when residual moisture in the blend exceeds 2.0 % w/w or when the punch-face temperature exceeds the softening point of the API; pre-drying of excipients is required at ambient relative humidity above 60 %.

What Limits Fluid-Bed Drying Uniformity After High-Shear Granulation?

High-shear wet granulation of 4-butylresorcinol introduces a thermal constraint that is rarely encountered with high-melting-point actives. In a high-shear granulator, the endpoint is controlled by impeller power consumption or torque; a fixed granulation time is not used because batch-to-batch variation in starting material properties shifts the endpoint. For a laboratory-scale granulator, impeller tip speed is typically held in the range of 5–8 m/s, and chopper speed is held at 1500–3000 rpm; these values are equipment-dependent starting points and require tip-speed equivalence during scale-up. The binder solution may be hypromellose E5 in purified water; povidone K30 is avoided unless its peroxide content is controlled to an internal oxidation-stability limit because the phenolic structure of 4-butylresorcinol is incompatible with strong oxidizing agents and peroxide residues. Drying is carried out in a fluid-bed dryer with inlet air temperature limited to 45–50 °C and product temperature held below 35 °C to remain below the melting point of the API. The drying endpoint is measured by loss on drying or by Karl Fischer titration using USP <921> Method Ic; a residual moisture target of 1.5–2.0 % w/w is used for tablet compression, while a tighter limit is applied if the granule is packed as a final oral granule dosage form. Bed depth in the fluid-bed dryer is limited to 10–15 cm to reduce moisture stratification and agglomeration. The dried granules are screened through a sieve with an aperture of 0.8–1.0 mm, then blended with extragranular disintegrant and lubricant. The resulting granulation may be compressed into tablets, filled into hard capsules, or packed into sachets as an oral granule dosage form; for sachet filling, the particle-size distribution is controlled by Ph. Eur. 2.9.12 or USP <786>, and fill-weight uniformity is evaluated by USP <905>. Published data for polymorphic stability of 4-butylresorcinol after high-shear wet granulation is limited; X-ray powder diffraction should be used to confirm unchanged crystal form before compressibility is assessed.

For capsule-based oral solid dosage forms, roller-compacted granules are produced when direct-compression blends fail a powder-flow threshold measured as a Carr index above 25 or when the API particle size requires densification for uniform filling. Dry granulation avoids the heat and moisture exposure of wet granulation; it is preferred when early stability data indicate hydrolytic or thermal degradation. A roller compactor with side-sealed rolls is operated at roll pressure 40–60 bar, roll speed 4–8 rpm, and gap 2–4 mm; these are typical starting ranges for microcrystalline cellulose-based formulations and must be optimized by design of experiments under ICH Q8. The ribbons are milled through a 1.0 mm screen, and the granule fraction between 125 µm and 1000 µm is collected; fines below 125 µm may be recycled but can increase sticking during subsequent capsule filling or tableting. Capsule filling is performed on a dosator or tamping-pin machine. For low-dose products, segregation during hopper vibration is controlled by sampling the filled capsules at the beginning, middle, and end of the fill campaign and by testing content uniformity according to USP <905>. Weight uniformity is also evaluated by USP <905>; dissolution is tested according to USP <711>. Because the API is poorly water-soluble, the dissolution method may require a surfactant-containing medium; the concentration of sodium lauryl sulfate is selected from solubility data at pH 1.2, 4.5, and 6.8, not from a fixed formula. USP Apparatus II at 50 rpm or 75 rpm in 900 mL of medium is a standard starting point. Published data for this specific compound in roller-compacted capsule formulations is limited; the granule and capsule parameters therefore require registration-batch confirmation.

Filter Adsorption and pH-Dependent Oxidation in Liquid Injectable Processing

In liquid injectable formulation development, a combined pH/cosolvent approach is required because the unionized phenol has low aqueous solubility, and ionization at high pH accelerates oxidative discoloration. The formulation pH is typically maintained between 5.0 and 6.5; at pH above 9.0 the phenolic hydroxyl groups become progressively ionized, improving solubility but increasing sensitivity to dissolved oxygen. Phosphate or citrate buffers are used at low concentration, and a cosolvent system such as PEG 400 or propylene glycol is added in the range of 10–30 % v/v; polysorbate 80 may be used at 0.05–0.2 % w/v to prevent precipitation upon dilution. The solution is sparged with nitrogen until dissolved oxygen is reduced to ≤0.5 mg/L, then filtered through a 0.22 µm polyethersulfone or PVDF membrane. Filter adsorption is evaluated as a formal development study because phenolic compounds can bind to membrane polymers; the acceptance criterion is set at ≤5.0 % loss of label claim, and the filter train is challenged with the actual formulation at maximum batch volume. Terminal sterilization at 121 °C for 15 min is evaluated only if forced-degradation data show no unacceptable degradation; otherwise aseptic filtration and aseptic filling are used. The container closure system consists of Type I borosilicate vials according to USP <660> and elastomeric closures according to USP <381>; extractables and leachables are assessed under USP <1663> and USP <1664>. The bulk solution is held under nitrogen, and maximum hold time is justified by chemical and bioburden stability data. Particulate matter in the final product is controlled by USP <788> Method 1; sterility by USP <71>; and bacterial endotoxins by USP <85> with the limit calculated from the maximum bolus dose using K/M, where K = 5 EU/kg. Published data for a finished liquid injectable 4-butylresorcinol product is limited; the above parameters are standard for oxygen-sensitive phenolic injectables and require product-specific validation.

Lyophilized 4-Butylresorcinol Requires Thermal Characterization Before Cycle Definition

When aqueous solution stability data at 2–8 °C show insufficient chemical stability, a lyophilized injection is designed. The formulation contains a bulking agent, usually mannitol or trehalose, and may include an antioxidant such as sodium metabisulfite at 0.05–0.1 % w/v. Thermal characterization by differential scanning calorimetry and freeze-dry microscopy is used to determine the glass transition and collapse temperature; a cycle cannot be transferred directly across vial sizes or freeze-dryer load volumes. A representative development cycle begins with freezing at −45 °C at a ramp rate of 0.5 °C/min, annealing at −20 °C for 2 h, primary drying at −25 °C shelf temperature and 0.2 mbar chamber pressure, and secondary drying at 25 °C and 0.1 mbar for 8 h; published data for the lyophilization of this specific compound is limited, and these parameters are representative starting points for low-concentration phenolic solutions. Residual moisture is measured by USP <921> Method Ic and controlled below 1.0 % w/w. After drying, the chamber is backfilled with dry nitrogen and the vials are stoppered; container closure integrity is verified by vacuum decay or dye ingress according to USP <1207>. Reconstitution with sterile water for injection should produce a clear to slightly opalescent solution within 2–3 min; the reconstituted product is then visually inspected for particulate matter. This dosage form reduces oxidative degradation by removing water and reducing headspace oxygen, but it does not eliminate the need for temperature-controlled storage if the API retains thermal sensitivity.

When Ethanol Is Selected as a Granulation Solvent to Reduce Residual Moisture

Non-aqueous granulation using ethanol or isopropanol is selected when aqueous granulation would require prolonged drying at elevated temperature or when the API shows hydrolytic instability. Ethanol is a Class 3 solvent under ICH Q3C; its residual level in the finished product is limited to 5000 ppm. The process is carried out in an explosion-proof high-shear granulator and a fluid-bed dryer fitted with nitrogen inerting; oxygen concentration is maintained below 25 % of the lower explosive limit. Because ethanol evaporates at lower temperature and with lower heat of vaporization than water, the inlet air temperature can be reduced to 35–40 °C, keeping the product temperature well below the melting point of 4-butylresorcinol. Drying time is often shortened, but solvent removal must be verified in the granulation before compression or capsule filling by headspace gas chromatography according to USP <467>. Equipment cleaning validation after solvent-based granulation uses swab sampling and HPLC assay for residual active pharmaceutical ingredient and gas chromatographic detection for residual solvent. This route is intended for high-potency low-dose granules where aqueous binder migration can cause content uniformity failures. The granule may be filled into sachets as a final oral granule dosage form; in that case, particle-size distribution by Ph. Eur. 2.9.12 or USP <786> and sachet fill-weight uniformity are added to the release specification.

For batch release of tablets, capsules, and oral granules, the analytical control strategy for 4-butylresorcinol pharma-grade API is structured around pharmacopoeial general chapters and ICH guidelines. Because no specific monograph exists for this compound as an oral or injectable API, the control strategy is developed under ICH Q3A, Q3C, Q3D, and ICH Q6A. The release and stability-indicating methods in the following matrix are selected for oral solid dosage forms; injectable-specific controls are addressed separately. The exact acceptance limits are product-specific and must be justified by batch data because no public monograph establishes a limit for this API in these dosage forms.

Stability protocols for these oral solid dosage forms follow ICH Q1A; storage at 25 °C/60 % RH long term and 40 °C/75 % RH accelerated is used unless API-specific degradation data indicate a more restrictive condition. The analytical methods are stability-indicating if forced-degradation studies show resolution of 4-butylresorcinol from its degradation products. Published data for this specific compound in oral solid dosage form is limited; therefore, the control strategy is refined after pilot-scale and registration stability batches.